KHPG(SZ:002773)2022-12-06 02:42Group 1: Company Overview - Kanghong Pharmaceutical is listed under stock code 002773 and is based in Chengdu, China [1] - The investor relations activity took place on April 28, 2017, with key executives present, including the Chairman and CEO [1][3] Group 2: Product Development and Research - The company is focusing on the consistency evaluation of generic drugs, specifically Aripiprazole orally disintegrating tablets, which have completed pharmaceutical research and submitted BE ethical review materials [3][4] - Ongoing clinical research preparations for KH704-R02 (Duloxetine Hydrochloride orally disintegrating tablets) and KH705-R01 (Esomeprazole Magnesium enteric-coated capsules) are in progress [5] - The company aims to develop high-end APIs and quality formulations, focusing on new molecules and formulations [4][6] Group 3: Innovation Strategy - The innovation strategy includes a combination of independent development and collaboration, focusing on core areas such as ophthalmology, central nervous system, digestive system, and oncology [5][6] - The company is also developing new traditional Chinese medicine products and expanding international cooperation for product globalization [6][9] Group 4: Market Expansion and Clinical Trials - KH906 has received clinical approval and is expected to address a significant market need for treating new blood vessel diseases post-injury and chemical burns [7][8] - The company plans to conduct large-sample clinical studies for Kangbaxip (康柏西普) from 2014 to 2019, covering over 5,000 subjects [8][9] Group 5: Regulatory and Market Challenges - The new medical insurance directory is expected to support innovative drugs and traditional Chinese medicine, enhancing their market presence [9][10] - The company is preparing for potential competition from foreign innovative drugs entering the Chinese market, with a robust intellectual property protection strategy in place [12][13] Group 6: Financial Outlook and Growth Potential - The introduction of Keluoxin capsules into the new medical insurance directory is anticipated to significantly boost sales, especially in the diabetic nephropathy market [10][11] - The company is actively seeking partnerships to expand its production capacity and meet future market demands [14]